Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsORALGeneric

PREVACID NAPRAPAC 375 (COPACKAGED)

LANSOPRAZOLE; NAPROXEN

Standard Dose
15MG,N/A;N/A,375MG
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Discontinued
Summary

Approval overview PREVACID NAPRAPAC 375 (COPACKAGED) is listed in Drugs@FDA under application 021507 (NDA).

Review priority: STANDARD Marketing status: Discontinued Active ingredient LANSOPRAZOLE; NAPROXEN Form and strength CAPSULE, DELAYED REL PELLETS, TABLET;ORAL - 15MG,N/A;N/A,375MG Sponsor TAKEDA PHARMS NA Submission history Latest submission status date: 2009-07-31 00:00:00.

Structured Monograph

Clinical summary

Approval overview PREVACID NAPRAPAC 375 (COPACKAGED) is listed in Drugs@FDA under application 021507 (NDA). Review priority: STANDARD Marketing status: Discontinued Active ingredient LANSOPRAZOLE; NAPROXEN Form and strength CAPSULE, DELAYED REL PELLETS, TABLET;ORAL - 15MG,N/A;N/A,375MG Sponsor TAKEDA PHARMS NA Submission history Latest submission status date: 2009-07-31 00:00:00. Submission type: SUPPL.

Monitoring

  • • Marketing status: Discontinued
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.